(Q43074099)

English

Omacetaxine mepesuccinate for patients with accelerated phase chronic myeloid leukemia with resistance or intolerance to two or more tyrosine kinase inhibitors

scientific article published on 10 June 2013

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

13 November 2017

Omacetaxine mepesuccinate for patients with accelerated phase chronic myeloid leukemia with resistance or intolerance to two or more tyrosine kinase inhibitors (English)

1 reference

Europe PubMed Central

PMC publication ID

13 November 2017

chronic myeloid leukemia

0 references

1 reference

based on heuristic

inferred from title

Hagop Kantarjian

5

object named as

Hagop Kantarjian

1 reference

Europe PubMed Central

PMC publication ID

13 November 2017

object named as

Delphine Rea

4

0 references

Jorge Eduardo Cortes

10

object named as

Jorge Cortes

1 reference

Europe PubMed Central

13 November 2017

PMC publication ID

Michele Baccarani

6

object named as

Michele Baccarani

1 reference

Europe PubMed Central

13 November 2017

PMC publication ID

Annie-Claude Benichou

9

object named as

Annie-Claude Benichou

1 reference

Europe PubMed Central

PMC publication ID

13 November 2017

3

object named as

Luke Akard

1 reference

Europe PubMed Central

PMC publication ID

13 November 2017

Janis Leonoudakis

7

object named as

Janis Leonoudakis

1 reference

Europe PubMed Central

PMC publication ID

13 November 2017

author name string

Franck E Nicolini

1

1 reference

Europe PubMed Central

PMC publication ID

13 November 2017

H Jean Khoury

2

1 reference

Europe PubMed Central

PMC publication ID

13 November 2017

Adam Craig

8

1 reference

Europe PubMed Central

PMC publication ID

13 November 2017

publication date

10 June 2013

1 reference

Europe PubMed Central

PMC publication ID

13 November 2017

1 reference

Europe PubMed Central

PMC publication ID

13 November 2017

98

1 reference

Europe PubMed Central

PMC publication ID

13 November 2017

7

1 reference

Europe PubMed Central

PMC publication ID

13 November 2017

e78-9

1 reference

Europe PubMed Central

PMC publication ID

13 November 2017

Subcutaneous omacetaxine mepesuccinate in patients with chronic-phase chronic myeloid leukemia previously treated with 2 or more tyrosine kinase inhibitors including imatinib

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3696599

25 May 2018

Inhibitory effects of omacetaxine on leukemic stem cells and BCR-ABL-induced chronic myeloid leukemia and acute lymphoblastic leukemia in mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3696599

25 May 2018

Anti-myeloma effect of homoharringtonine with concomitant targeting of the myeloma-promoting molecules, Mcl-1, XIAP, and beta-catenin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3696599

25 May 2018

A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3696599

25 May 2018

Semisynthetic homoharringtonine induces apoptosis via inhibition of protein synthesis and triggers rapid myeloid cell leukemia-1 down-regulation in myeloid leukemia cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3696599

25 May 2018

Alkaloid homoharringtonine inhibits polypeptide chain elongation on human ribosomes on the step of peptide bond formation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3696599

25 May 2018

Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3696599

15 August 2018

Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3696599

3 November 2018

Omacetaxine may have a role in chronic myeloid leukaemia eradication through downregulation of Mcl-1 and induction of apoptosis in stem/progenitor cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/23753022

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.3324/HAEMATOL.2012.083006

1 reference

Europe PubMed Central

PMC publication ID

13 November 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

13 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

13 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43074099&oldid=1980090239"